REPLIGEN CORP (RGEN) Stock Fundamental Analysis
NASDAQ:RGEN • US7599161095
124.97 USD
-3.76 (-2.92%)
At close: Mar 2, 2026
124.97 USD
0 (0%)
After Hours: 3/2/2026, 8:00:02 PM
We assign a fundamental rating of 5 out of 10 to RGEN. RGEN was compared to 57 industry peers in the Life Sciences Tools & Services industry. RGEN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- RGEN had positive earnings in the past year.
- In the past year RGEN had a positive cash flow from operations.
- RGEN had positive earnings in 4 of the past 5 years.
- RGEN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With a decent Return On Assets value of 1.66%, RGEN is doing good in the industry, outperforming 70.18% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 2.32%, RGEN is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
- RGEN has a better Return On Invested Capital (1.65%) than 61.40% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 11.60%.
- The last Return On Invested Capital (1.65%) for RGEN is above the 3 year average (1.41%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.66% | ||
| ROE | 2.32% | ||
| ROIC | 1.65% |
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.41%
ROIC(5y)3.7%
1.3 Margins
- With a decent Profit Margin value of 6.62%, RGEN is doing good in the industry, outperforming 75.44% of the companies in the same industry.
- In the last couple of years the Profit Margin of RGEN has declined.
- Looking at the Operating Margin, with a value of 8.03%, RGEN is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
- In the last couple of years the Operating Margin of RGEN has declined.
- RGEN has a Gross Margin of 52.65%. This is in the better half of the industry: RGEN outperforms 68.42% of its industry peers.
- In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.03% | ||
| PM (TTM) | 6.62% | ||
| GM | 52.65% |
OM growth 3Y-32.64%
OM growth 5Y-17.99%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.73%
GM growth 5Y-1.78%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
- The number of shares outstanding for RGEN has been increased compared to 1 year ago.
- The number of shares outstanding for RGEN has been increased compared to 5 years ago.
- Compared to 1 year ago, RGEN has an improved debt to assets ratio.
2.2 Solvency
- RGEN has an Altman-Z score of 6.09. This indicates that RGEN is financially healthy and has little risk of bankruptcy at the moment.
- RGEN has a Altman-Z score of 6.09. This is amongst the best in the industry. RGEN outperforms 91.23% of its industry peers.
- RGEN has a debt to FCF ratio of 5.91. This is a neutral value as RGEN would need 5.91 years to pay back of all of its debts.
- RGEN has a better Debt to FCF ratio (5.91) than 68.42% of its industry peers.
- A Debt/Equity ratio of 0.26 indicates that RGEN is not too dependend on debt financing.
- The Debt to Equity ratio of RGEN (0.26) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.91 | ||
| Altman-Z | 6.09 |
ROIC/WACC0.16
WACC10.61%
2.3 Liquidity
- RGEN has a Current Ratio of 8.37. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 8.37, RGEN belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
- A Quick Ratio of 7.12 indicates that RGEN has no problem at all paying its short term obligations.
- RGEN has a Quick ratio of 7.12. This is amongst the best in the industry. RGEN outperforms 89.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.37 | ||
| Quick Ratio | 7.12 |
3. Growth
3.1 Past
- RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.54%, which is quite good.
- RGEN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.60% yearly.
- RGEN shows a decrease in Revenue. In the last year, the revenue decreased by -6.05%.
- RGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.05% yearly.
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%
3.2 Future
- The Earnings Per Share is expected to grow by 26.12% on average over the next years. This is a very strong growth
- Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 17.04% on average per year.
EPS Next Y24.26%
EPS Next 2Y25.75%
EPS Next 3Y28.24%
EPS Next 5Y26.12%
Revenue Next Year12.44%
Revenue Next 2Y13.71%
Revenue Next 3Y15.06%
Revenue Next 5Y17.04%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 73.08, the valuation of RGEN can be described as expensive.
- RGEN's Price/Earnings ratio is in line with the industry average.
- When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (27.13), we can say RGEN is valued expensively.
- A Price/Forward Earnings ratio of 58.81 indicates a quite expensive valuation of RGEN.
- RGEN's Price/Forward Earnings ratio is in line with the industry average.
- RGEN is valuated expensively when we compare the Price/Forward Earnings ratio to 28.11, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 73.08 | ||
| Fwd PE | 58.81 |
4.2 Price Multiples
- RGEN's Enterprise Value to EBITDA ratio is in line with the industry average.
- RGEN's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 76.72 | ||
| EV/EBITDA | 49.4 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- RGEN has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as RGEN's earnings are expected to grow with 28.24% in the coming years.
PEG (NY)3.01
PEG (5Y)122.77
EPS Next 2Y25.75%
EPS Next 3Y28.24%
5. Dividend
5.1 Amount
- No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
124.97
-3.76 (-2.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24 2026-02-24/bmo
Earnings (Next)04-27 2026-04-27/bmo
Inst Owners110.6%
Inst Owner Change0.02%
Ins Owners0.45%
Ins Owner Change-2.86%
Market Cap7.03B
Revenue(TTM)738.26M
Net Income(TTM)48.89M
Analysts81.43
Price Target191.52 (53.25%)
Short Float %7.73%
Short Ratio6.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.52%
Min EPS beat(2)7.78%
Max EPS beat(2)9.25%
EPS beat(4)3
Avg EPS beat(4)5.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)5
Avg EPS beat(8)5.28%
EPS beat(12)8
Avg EPS beat(12)7.82%
EPS beat(16)12
Avg EPS beat(16)10.63%
Revenue beat(2)2
Avg Revenue beat(2)1.33%
Min Revenue beat(2)0.58%
Max Revenue beat(2)2.07%
Revenue beat(4)4
Avg Revenue beat(4)1.51%
Min Revenue beat(4)0.58%
Max Revenue beat(4)2.15%
Revenue beat(8)4
Avg Revenue beat(8)-0.01%
Revenue beat(12)4
Avg Revenue beat(12)-0.88%
Revenue beat(16)7
Avg Revenue beat(16)0.5%
PT rev (1m)-1.21%
PT rev (3m)0.18%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)0.05%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 73.08 | ||
| Fwd PE | 58.81 | ||
| P/S | 9.53 | ||
| P/FCF | 76.72 | ||
| P/OCF | 59.91 | ||
| P/B | 3.34 | ||
| P/tB | 11.62 | ||
| EV/EBITDA | 49.4 |
EPS(TTM)1.71
EY1.37%
EPS(NY)2.12
Fwd EY1.7%
FCF(TTM)1.63
FCFY1.3%
OCF(TTM)2.09
OCFY1.67%
SpS13.12
BVpS37.42
TBVpS10.76
PEG (NY)3.01
PEG (5Y)122.77
Graham Number37.94
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.66% | ||
| ROE | 2.32% | ||
| ROCE | 2.11% | ||
| ROIC | 1.65% | ||
| ROICexc | 2.27% | ||
| ROICexgc | 8.52% | ||
| OM | 8.03% | ||
| PM (TTM) | 6.62% | ||
| GM | 52.65% | ||
| FCFM | 12.42% |
ROA(3y)0.67%
ROA(5y)2.96%
ROE(3y)0.95%
ROE(5y)3.98%
ROIC(3y)1.41%
ROIC(5y)3.7%
ROICexc(3y)1.96%
ROICexc(5y)5.25%
ROICexgc(3y)7.26%
ROICexgc(5y)30.39%
ROCE(3y)1.8%
ROCE(5y)4.72%
ROICexgc growth 3Y-47.07%
ROICexgc growth 5YN/A
ROICexc growth 3Y-40.95%
ROICexc growth 5Y-20.55%
OM growth 3Y-32.64%
OM growth 5Y-17.99%
PM growth 3Y-34.16%
PM growth 5Y-16.54%
GM growth 3Y-2.73%
GM growth 5Y-1.78%
F-Score6
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.91 | ||
| Debt/EBITDA | 3.93 | ||
| Cap/Depr | 32.68% | ||
| Cap/Sales | 3.49% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 85.06% | ||
| Profit Quality | 187.52% | ||
| Current Ratio | 8.37 | ||
| Quick Ratio | 7.12 | ||
| Altman-Z | 6.09 |
F-Score6
WACC10.61%
ROIC/WACC0.16
Cap/Depr(3y)44.28%
Cap/Depr(5y)98.33%
Cap/Sales(3y)4.79%
Cap/Sales(5y)7.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.54%
EPS 3Y-19.52%
EPS 5Y0.6%
EPS Q2Q%11.36%
EPS Next Y24.26%
EPS Next 2Y25.75%
EPS Next 3Y28.24%
EPS Next 5Y26.12%
Revenue 1Y (TTM)-6.05%
Revenue growth 3Y-2.7%
Revenue growth 5Y15.05%
Sales Q2Q%18.12%
Revenue Next Year12.44%
Revenue Next 2Y13.71%
Revenue Next 3Y15.06%
Revenue Next 5Y17.04%
EBIT growth 1Y282.37%
EBIT growth 3Y-34.46%
EBIT growth 5Y-5.65%
EBIT Next Year82.74%
EBIT Next 3Y47.35%
EBIT Next 5Y37.69%
FCF growth 1Y-36.98%
FCF growth 3Y3.04%
FCF growth 5Y20.36%
OCF growth 1Y-33.06%
OCF growth 3Y-11.97%
OCF growth 5Y13.4%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status for RGEN stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 6 / 10.
What is the financial health of REPLIGEN CORP (RGEN) stock?
The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.
What is the earnings growth outlook for REPLIGEN CORP?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 24.26% in the next year.